Better patient experience and faster methodologies...BD
Vidacare, the leading developer, manufacturer and marketer of advanced intraosseous technology, announced it has received 510(k) clearance from the U.S. Food and Drug Administration to market its new bone marrow biopsy (trephine) system. With its lithium-powered driver, Vidacare's OnControl™ Bone Marrow Biopsy System represents the first effort in decades to improve the speed, control, core capture rate, and patient comfort of the bone marrow biopsy procedure.
"The FDA's approval of the OnControl Biopsy System is a key milestone for Vidacare as well as patients requiring bone marrow biopsies," says Philip Faris Jr., CEO and president of Vidacare. "Bone marrow biopsies are the most frequently performed intraosseous diagnostic procedure in the U.S. and around the world. Virtually unchanged for decades, the manual procedure causes pain rated as severe to worst possible pain by nearly 20 per cent of patients participating in a recent study. The goal of the OnControl Biopsy System is to provide greater clinician control while increasing the core capture rate, and decreasing the discomfort experienced by patients and clinicians."
Vidacare Announces Clearance Of Novel Bone Marrow Biopsy System For Hematology/Oncology
0 comments :
Post a Comment